Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.950
+0.060 (3.17%)
Nov 28, 2025, 4:00 PM EST - Market closed

Innate Pharma Revenue

Innate Pharma had revenue of 4.86M EUR in the half year ending June 30, 2025, a decrease of -87.91%. This brings the company's revenue in the last twelve months to 12.64M, down -62.60% year-over-year. In the year 2024, Innate Pharma had annual revenue of 20.12M, down -67.36%.

Revenue (ttm)
12.64M EUR
Revenue Growth
-62.60%
P/S Ratio
12.30
Revenue / Employee
69,812 EUR
Employees
181
Market Cap
182.58M USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 202069.77M-15.68M-18.35%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group435.16B
Johnson & Johnson92.15B
Merck & Co.64.24B
AbbVie59.64B
Eli Lilly and Company59.42B
AstraZeneca58.13B
Novartis AG56.37B
Novo Nordisk49.58B
Revenue Rankings